Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1Leiomyoma 1Colorectal Neoplasms 1Anemia, Iron-Deficiency 1Anemia 1

Interventions

Rituximab 301Cyclophosphamide 241Peripheral Blood Stem Cell Transplantation 115fludarabine phosphate 111Filgrastim 93Etoposide 85Radiotherapy 81Lenalidomide 81Vincristine 79Prednisone 79Mycophenolic Acid 67Doxorubicin 62Whole-Body Irradiation 59Cyclosporine 59Bendamustine Hydrochloride 59Melphalan 57Tacrolimus 54Busulfan 52obinutuzumab 50fludarabine 50Cytarabine 49Methotrexate 45Antilymphocyte Serum 43Bortezomib 42Methylprednisolone 37Carmustine 37sargramostim 36ibritumomab tiuxetan 33ibrutinib 30Dexamethasone 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × Iron × Clear all
NCT03993288 2021-07-12

Study to Test the Hypothesis of Non-inferior Efficacy and Safety of Ferrum LekĀ® (Iron (III) Hydroxide Polymaltosate), 100 mg Chewable Tablets (Lek d.d., Slovenia), as Compared With MALTOFERĀ® (Vifor S.A., Switzerland), in Subjects With Mild and Moderate Iron Deficiency Anemia.

Sandoz

Phase 3 Completed
267 enrolled 14 charts
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚔